Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756997 | 0.89 | ELANE (0.58) | ELANECYP2C9CYP3A4NOTUMRXFP1 | |
| SCHEMBL5758928 | 0.88 | ELANE (0.57) | ELANECYP2C9CYP3A4NOTUMALDH1A1 | |
| SCHEMBL5757787 | 0.88 | ELANE (0.59) | ELANENOTUMRXFP1ALDH1A1POLB | |
| SCHEMBL5759333 | 0.87 | ELANE (0.56) | ELANENOTUMRXFP1ALDH1A1POLB | |
| SCHEMBL5759697 | 0.87 | ELANE (0.56) | ELANECYP2C9CYP3A4NOTUMRXFP1 | |
| SCHEMBL5757746 | 0.85 | ELANE (0.74) | ELANECYP2C9 | |
| SCHEMBL5758842 | 0.85 | ELANE (0.74) | ELANENOTUMRXFP1ALDH1A1POLB | |
| SCHEMBL5442962 | 0.83 | ELANE (0.48) | ELANECYP2C9CYP3A4RXFP1 | |
| SCHEMBL561046 | 0.78 | NOTUM (0.68) | ELANENOTUMALDH1A1POLBGAA | |
| SCHEMBL5757554 | 0.78 | ELANE (0.73) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885CYP2C9 1239/4885CYP3A4 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.